Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
about
Endothelial progenitor cells: what use for the cardiologist?Cardiovascular diabetology in the core of a novel interleukins classification: the bad, the good and the aloofCharacterization of a novel endothelial biosensor assay reveals increased cumulative serum inflammatory potential in stabilized coronary artery disease patientsRosiglitazone for type 2 diabetes mellitusWaist circumference as the predominant contributor to the micro-inflammatory response in the metabolic syndrome: a cross sectional studyFibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markersParallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgammaRisk factors in coronary atherosclerosis athero-inflammation: the meeting pointThe antithrombotic profile of aspirin. Aspirin resistance, or simply failure?PPARĪ³ and the Innate Immune System Mediate the Resolution of InflammationBreaking the mold: transcription factors in the anucleate platelet and platelet-derived microparticlesA new look at auranofin, dextromethorphan and rosiglitazone for reduction of glia-mediated inflammation in neurodegenerative diseasesRole of C-reactive protein in cardiovascular diseaseC-reactive protein, cardiovascular disease and stroke: new roles for an old biomarkerC-reactive protein (CRP)-lowering agentsThe role of fatty acid binding proteins in metabolic syndrome and atherosclerosisA SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gammaThe current role of thiazolidinediones in diabetes management.Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, protects pancreas against acute cerulein-induced pancreatitis.Anti-inflammatory effect of rosiglitazone is not reflected in expression of NFkappaB-related genes in peripheral blood mononuclear cells of patients with type 2 diabetes mellitus.Genome-wide mRNA expression analysis of hepatic adaptation to high-fat diets reveals switch from an inflammatory to steatotic transcriptional program.Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT)Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial.Differential white blood cell count and type 2 diabetes: systematic review and meta-analysis of cross-sectional and prospective studies.Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes.Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retentionMediation role of C-reactive protein on the association between smoking quantity and type 2 diabetes in current Chinese smokers.Rosiglitazone reduces blood pressure in female Dahl salt-sensitive ratsHigh-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazoneIntensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose toleranceAssociation of SELE genotypes/haplotypes with sE-selectin levels in Taiwanese individuals: interactive effect of MMP9 level.Changes of body weight and inflammatory markers after 12-week intervention trial: results of a double-blind, placebo-control pilot study.Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity--a common inflammatory phenotype?PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression.Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study).Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.The macrophage foam cell as a target for therapeutic intervention.PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophagesThiazolidinediones -- some recent developments.Vascular inflammation and endothelial dysfunction in experimental hypertension.
P2860
Q21198698-B1C116C2-614E-4487-869F-48A0F587BC04Q21246039-A67582CA-A9B8-4E78-A639-8D7B59276F55Q23913506-DAD66D58-3F34-4B53-9B83-9702EB50EEA2Q24243875-8E76CC82-3330-4508-B0FE-E66A6C14344BQ24633407-49669BBC-8EED-4D12-B137-80D737B1504FQ24644869-A00928FC-323F-4FEF-91B8-8851AA39B215Q24685818-E331D77E-D056-4E66-BB4D-72514E6108A6Q24793107-E5BD8C25-4F68-4D48-8224-4E8D2B9E41C0Q24794673-AE54301B-6527-467C-AC51-1C2C34436754Q26771755-F93B3F00-B062-49C0-ACA4-887B5FFC84DCQ26830366-EAB913E7-FB91-44A8-8509-BDD2C0B54684Q27005806-FD54BC08-4449-484D-A791-371EFEBBC333Q28166927-B932A371-6485-4273-8B4B-ACACD1637C58Q28174368-7A1D869E-5CE9-46B0-90D4-78AE4CB0CE3CQ28200344-9FA52C10-A01E-472E-BEBE-F54CF7C6118BQ28271189-91FC6677-3FE3-4AA4-A89B-4B2D181B60CBQ28593737-1242119C-55D4-4767-B01D-4C7C6ACEC495Q30250347-9970F9BA-7D10-47B4-A8AF-98818E4C402FQ33231851-6EB9692A-FB01-4DB5-999B-09A43548D123Q33412579-868269E3-4D71-495E-A336-F56B85D87FECQ33493427-D79520B2-1010-4373-834D-00AE3B077006Q33556796-5672DB9A-5B18-44B5-85DA-6B018426ED58Q33683750-7203A725-6CE2-47B8-95A5-F7BC03142A13Q33728315-36E252A8-186D-4C3E-A418-2EC6EDB2343FQ33827960-355E8DCD-4F81-4665-869D-5553686058C9Q33878917-97EBF5B8-D47E-44D6-98D7-E102E970B24BQ33930272-2EBDB0EA-3C93-4E7A-BF6E-713B017CFC57Q33937349-70039CC9-0D50-4C42-AA57-5C55A700A820Q33979763-FDED5CE4-CFC6-4F48-AD80-846A46CB2395Q34225645-56651B23-489F-46CC-B501-9C1D2096A846Q34494426-05B916DB-1D27-488F-8F55-56655BCD835EQ34635464-3868CAE4-4BF0-4D6C-AEAD-B0A54B188BFBQ34684222-67AFB22E-0A71-4D19-B544-9D73FE9C1D99Q34689526-997DF99A-B0B4-4700-8263-53A2F63121D3Q34774079-1CC1FC52-55DF-4098-ADC6-71E34BFBD3C6Q34781949-61F22203-24B4-4059-80D2-D9A01AD22B00Q34986351-73FB5887-CB8B-4E5B-9EC3-39C61C8CF100Q35144057-56836158-AC75-4B56-B0EF-7A3464F629B5Q35164761-D5FFB1A4-41A6-4EBE-B4F7-BDA58FAFBE26Q35207893-42E695A2-3F45-47A5-AAAE-EC100815216A
P2860
Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
description
2002 nĆ® lÅ«n-bĆ»n
@nan
2002 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« ÕÕ£ÕøÕ½ÕæÕøÕ½Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2002 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« Ö
Õ£ÕøÕ½ÕæÕøÕ½Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2002幓ć®č«ę
@ja
2002幓č«ę
@yue
2002幓č«ę
@zh-hant
2002幓č«ę
@zh-hk
2002幓č«ę
@zh-mo
2002幓č«ę
@zh-tw
2002幓č®ŗę
@wuu
name
Effect of rosiglitazone treatm ...... with type 2 diabetes mellitus.
@ast
Effect of rosiglitazone treatm ...... with type 2 diabetes mellitus.
@en
Effect of rosiglitazone treatm ...... with type 2 diabetes mellitus.
@nl
type
label
Effect of rosiglitazone treatm ...... with type 2 diabetes mellitus.
@ast
Effect of rosiglitazone treatm ...... with type 2 diabetes mellitus.
@en
Effect of rosiglitazone treatm ...... with type 2 diabetes mellitus.
@nl
prefLabel
Effect of rosiglitazone treatm ...... with type 2 diabetes mellitus.
@ast
Effect of rosiglitazone treatm ...... with type 2 diabetes mellitus.
@en
Effect of rosiglitazone treatm ...... with type 2 diabetes mellitus.
@nl
P2093
P921
P1433
P1476
Effect of rosiglitazone treatm ...... with type 2 diabetes mellitus.
@en
P2093
Andrew S Greenberg
Hongzi Chen
Ken Williams
Martin I Freed
Steven M Haffner
Wayde M Weston
P304
P356
10.1161/01.CIR.0000025403.20953.23
P407
P577
2002-08-01T00:00:00Z